A clinician trained to manage reactions should be on-site at any imaging facilities doing contrast studies to maintain patient safety.

Here are some interesting new technologies and key trends from the vast expo floor at the Radiological Society of North America 2022 meeting.

The Sept. 21 announcement states that Gadopiclenol Injection—a highly stable macrocyclic gadolinium-based contrast agent—is approved for use in adult and pediatric patients aged 2 years and older during MRI exams.

Arl Van Moore, MD, American College of Radiology (ACR) delegate to the American Medical Association House of Delegates, former ACR president, chairman of the ACR Board and former CEO of Strategic Radiology, discusses radiology-related policy decisions at the AMA 2022 meeting.

Brian Ghoshhajra, MD, MBA, division chief, cardiovascular imaging, Massachusetts General Hospital and associate professor of radiology, Harvard Medical School, explains the impact of the iodine contrast shortage on computed tomography (CT) and cardiac imaging.
 

Production at the facility in Shanghai is expected to be near 100% starting on June 6.

The American College of Radiology (ACR) announced this week its government relations staff has been engaging federal agencies in an effort to improve product availability and hasten resolution of the ongoing iodine contrast shortage.

Alan Matsumoto, MD, chair of the department of radiology at the University of Virginia and vice chair of the ACR Board of Chancellors, explains how the ACR and group purchasing organizations are asking the FDA to mitigate the contrast shortage with an emergency use authorization to allow non-FDA cleared iodine contrast agents to be imported.